![](https://endpts.com/wp-content/uploads/link_thumbnails/131373_21b-or-bust-abbvie-ensures-its-blockbuster-us-marathon-on-humira-will-run-into-2023.jpg)
Remember that mega-blockbuster valuation AbbVie assigned to Rova-T? It’s starting to vanish — quietly
AbbVie execs have finally gotten around to doing what a host of analysts managed to accomplish long ago: writing down the value of their once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.